CERENO SCIENTIFIC AB (PUBL)

At Cereno, we have the potential to deliver high treatment value to patients leveraging our innovative pipeline and disease-modifying approach to address the root mechanism of rare and fatal diseases. We are committed to pioneering treatments to enhance and extend life for people suffering from rare cardiovascular and pulmonary diseases, who today have unmet medical needs... We are advancing an innovative pipeline that includes an HDACi portfolio with two drug candidates in clinical phase, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. In preclinical stage, our drug candidate CS585, a novel prostacyclin (IP) receptor agonist, has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease... Cereno Scientific strives to disrupt cardiovascular treatments worldwide by unlocking the potential of epigenetic modulation...

Also known as: Cereno, Cereno Scientific